Castle Biosciences, Inc.
CSTL
$24.06
$0.502.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.05% | 1.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.05% | 1.94% | |||
| Cost of Revenue | 7.59% | 1.24% | |||
| Gross Profit | -4.25% | 2.11% | |||
| SG&A Expenses | -0.95% | 17.32% | |||
| Depreciation & Amortization | -93.08% | 552.65% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.98% | 40.91% | |||
| Operating Income | 84.78% | -789.58% | |||
| Income Before Tax | 99.46% | -433.18% | |||
| Income Tax Expenses | -1,003.07% | 75.19% | |||
| Earnings from Continuing Operations | 117.50% | -369.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 117.50% | -369.53% | |||
| EBIT | 84.78% | -789.58% | |||
| EBITDA | -145.59% | -81.30% | |||
| EPS Basic | 117.31% | -364.96% | |||
| Normalized Basic EPS | 94.71% | -433.21% | |||
| EPS Diluted | 116.60% | -387.65% | |||
| Normalized Diluted EPS | 94.82% | -457.81% | |||
| Average Basic Shares Outstanding | 1.07% | 1.72% | |||
| Average Diluted Shares Outstanding | 3.27% | -5.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||